AbbVie Sees Reported GAAP Earnings And Adj Non-GAAP Earnings For Q2 To Include Acquired IPR&D And Milestones Expense Of $28M On Pre-Tax Basis; Q2 Adj EPS Guidance Range, Including The Impact Of Q2 2023 Acquired IPR&D And Milestones Expense Is $2.75-$2.85
Portfolio Pulse from Happy Mohamed
AbbVie has announced that its Q2 GAAP and non-GAAP earnings will include an acquired IPR&D and milestones expense of $28M on a pre-tax basis. The company's Q2 adjusted EPS guidance range, which includes the impact of the acquired IPR&D and milestones expense, is $2.75-$2.85.
July 06, 2023 | 8:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AbbVie's Q2 earnings will include a $28M expense for acquired IPR&D and milestones. The adjusted EPS guidance range is $2.75-$2.85.
The news directly pertains to AbbVie's Q2 earnings, which will include a significant expense for acquired IPR&D and milestones. This could potentially impact the company's profitability for the quarter, but the adjusted EPS guidance range remains relatively stable. Therefore, the short-term impact on the stock price is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100